KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Account Payables (2024 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Change in Account Payables for 2 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 129.78% year-over-year to $1.1 million, compared with a TTM value of -$1.9 million through Dec 2025, down 317.91%, and an annual FY2025 reading of -$1.9 million, down 317.91% over the prior year.
  • Change in Account Payables was $1.1 million for Q4 2025 at Aurinia Pharmaceuticals, up from -$1.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.7 million in Q2 2024 and bottomed at -$3.7 million in Q4 2024.